Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes

Leukemia
Didier BouscaryM Fontenay-Roupie

Abstract

Apoptosis of hematopoietic progenitor cells is increased in myelodysplastic syndromes (MDS). We have studied Fas (CD95/Apo-1) antigen expression in 27 MDS patients (RARS 4, RA 3, RAEB 13; RAEB-t 3, CMML 4) and three AML secondary to MDS. We found that the Fas antigen was not expressed on normal bone marrow (BM) CD34+, CD14+, or glycophorin+ cells, and only slightly on CD33+ cells. Patients with MDS had upregulation of Fas expression on total bone marrow nuclear cells (BMMC) (t-test, P = 0.04), CD34+ (P = 0.013), CD33+ (P = 0.04), and glycophorin+ (P = 0.032) BM cells compared to controls. Fas expression did not correlate to the FAB subtype, the Bournemouth score, or to peripheral cytopenias. However, Fas expression intensity on CD34+ cells negatively correlated to the BM blasts number (Spearman, P = 0.01) suggesting that leukemic blasts cells lose Fas antigen expression with progression of myelodysplasia. Using both proliferation assays in liquid cultures and clonogenic progenitor assays in the presence of an agonist anti-Fas MoAb (CH11), we showed that the Fas protein was functional in some patients. Dose-dependent inhibition of DNA synthesis was observed in three out of seven patients studied. CFU-GM and BFU-E colonies suppre...Continue Reading

Citations

Aug 16, 2001·International Journal of Hematology·Jane E Parker, Ghulam J Mufti
May 4, 2010·International Journal of Hematology·Cagatay OktenliSelim Nalbant
Jan 22, 2004·Archives of Medical Research·Suneel D Mundle
Oct 21, 2004·Best Practice & Research. Clinical Haematology·Ghulam J Mufti
Sep 4, 1999·Leukemia Research·Y Yoshida, G J Mufti
Aug 5, 2005·Oncogene·Sophie LaunayCarmen Garrido
Aug 8, 2006·Oncogene·M FontenayE Solary
Jun 3, 1998·British Journal of Haematology·J E Parker, G J Mufti
Nov 25, 1998·British Journal of Haematology·T OtsukiA Ueki
Sep 21, 2000·British Journal of Haematology·K ShimazakiM Kikuchi
Sep 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emmanuelle PasseguéIrving L Weissman
Oct 24, 2001·Journal of Hematotherapy & Stem Cell Research·A OdaK Sawada
Apr 24, 2008·Human Molecular Genetics·Bozena NovotnaYana Bagryantseva
Apr 29, 2000·Current Opinion in Hematology·A A AprikyanD C Dale
May 10, 2002·Leukemia & Lymphoma·K ShimazakiM Kikuchi
Oct 8, 2013·Expert Review of Hematology·Bishoy FaltasUsama Gergis
Feb 19, 2016·Journal of Immunoassay & Immunochemistry·Cristina MambetCarmen C Diaconu
Nov 5, 2013·Critical Reviews in Oncology/hematology·Heidrun KarlicMichael Pfeilstöcker
Jul 12, 2002·American Journal of Hematology·Delphine BoudardLydia Campos
Apr 3, 2010·Hematology/oncology Clinics of North America·Elaine M Sloand, A J Barrett
Dec 11, 2007·Blood Reviews·Eva Hellström-Lindberg, Luca Malcovati
Jan 9, 2008·Seminars in Hematology·Eva Hellström-Lindberg, Luca Malcovati
Jan 9, 2008·Seminars in Hematology·Elaine M Sloand, Katayoun Rezvani
Nov 3, 2007·Experimental Hematology·Daniella B Kerbauy, H Joachim Deeg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.